Back
Our Progress in 2023 and Plans for 2024 — Open Philanthropy (March 27, 2024)
webCredibility Rating
4/5
High(4)High quality. Established institution or organization with editorial oversight and accountability.
Rating inherited from publication venue: Coefficient Giving
Open Philanthropy is one of the largest funders of AI safety research; their annual reviews provide insight into how major philanthropic capital is being directed across the AI safety ecosystem and what priorities are shaping the field.
Metadata
Importance: 55/100organizational reportnews
Summary
Open Philanthropy's annual review covering their 2023 grantmaking activities and strategic priorities for 2024, with significant focus on AI safety funding. The report details how the organization is allocating resources across global catastrophic risks, biosecurity, and AI alignment, reflecting their evolving views on AI timelines and risk.
Key Points
- •Open Philanthropy significantly increased AI safety grantmaking in response to accelerating AI capabilities and shortened timelines to transformative AI.
- •The report outlines strategic shifts in funding priorities, including expanded support for technical AI safety research and governance work.
- •Discusses internal debates about how to best allocate limited philanthropic resources across near-term and long-term AI risk reduction.
- •Covers non-AI areas including global health, animal welfare, and biosecurity alongside AI-focused work.
- •Reflects on lessons learned from 2023 grantmaking and adjusts 2024 strategy based on the rapidly changing AI landscape.
Cited by 1 page
| Page | Type | Quality |
|---|---|---|
| Longtermism's Philosophical Credibility After FTX | -- | 50.0 |
Cached Content Preview
HTTP 200Fetched Mar 20, 202668 KB
[Skip to Content](https://coefficientgiving.org/research/our-progress-in-2023-and-plans-for-2024/#content)
March 27, 2024
# Our Progress in 2023 and Plans for 2024
By
Alexander Berger
**_Editor’s note:_** _This article was published under our former name, Open Philanthropy. Some content may be outdated. You can see our latest writing [here](https://coefficientgiving.org/research-and-news)_ _._
Like many organizations, Open Philanthropy has had multiple founding moments. Depending on [how](https://coefficientgiving.org/research/the-open-philanthropy-project-is-now-an-independent-organization/) [you](https://blog.givewell.org/2014/08/20/open-philanthropy-project-formerly-givewell-labs/) [count](https://blog.givewell.org/2011/09/08/announcing-givewell-labs/), we will be either seven, ten, or thirteen years old this year. Regardless of when you start the clock, it’s possible that we’ve changed more in the last two years than over our full prior history. We’ve more than doubled the size of our team (to ~110), nearly doubled our annual giving (to >$750M), and [added](https://coefficientgiving.org/focus/global-aid-policy/) [five](https://coefficientgiving.org/focus/global-health-rd/) [new](https://coefficientgiving.org/focus/global-public-health-policy/) [program](https://coefficientgiving.org/focus/innovation-policy/) [areas](https://coefficientgiving.org/focus/ea-global-health-and-wellbeing/).
As our track record and volume of giving have grown, we are seeing more of our impact in the world. Across our focus areas, our funding played a (sometimes modest) role in some of 2023’s most important developments:
- We were among the supporters of the [clinical trials](https://openphilanthropy.org/grants/?q=malaria+vaccine+phase+III) that led to the World Health Organization (WHO) [officially recommending](https://www.who.int/news/item/02-10-2023-who-recommends-r21-matrix-m-vaccine-for-malaria-prevention-in-updated-advice-on-immunization) the R21 malaria vaccine. This is the second malaria vaccine recommended by WHO, which expects it to enable “sufficient vaccine supply to benefit all children living in areas where malaria is a public health risk.” Although the late-stage clinical trial funding was Open Philanthropy’s first involvement with R21 research, that isn’t the case for our new global health R&D program officer, [Katharine Collins](https://coefficientgiving.org/team/katharine-collins/), who invented R21 as a grad student.
- Our early commitment to AI safety has contributed to increased awareness of the associated risks and to early steps to reduce them. The Center for AI Safety, [one of our AI grantees](https://openphilanthropy.org/grants/center-for-ai-safety-general-support-2023/), made [headlines](https://coefficientgiving.org/wp-content/uploads/nytimes.com-AI-Poses-Risk-of-Extinction-Industry-Leaders-Warn.pdf) [across](https://www.independent.co.uk/space/rishi-sunak-san-francisco-siri-government-prime-minister-b2348994.html) the [globe](http
... (truncated, 68 KB total)Resource ID:
b2aca6c9ac16eb73 | Stable ID: YTNjNzYxOT